Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
IEEE Journal of Biomedical and Health Informatics
|
May 24, 2023
Handling Ill-Conditioned Omics Data With Deep Probabilistic Models
Maria Martinez-Garcia, Pablo M Olmos
Frontiers in Oncology
|
January 3, 2025
Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports
Tamara Martos, Marta Saint-Gerons, Laura Masfarre, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|
September 10, 2019
Prognostic value of stem cell markers in glioblastoma
Francesc Alameda, José María Velarde, Cristina Carrato, et al.
Translational Oncology
|
December 18, 2020
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies
Florian Heil, Galina Babitzki, Alice Julien-Laferriere, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2012
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors
Maria Martinez-Garcia, Udai Banerji, Joan Albanell, et al.
ESMO Open
|
August 20, 2019
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer
Juan-Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas Kanonnikoff, et al.
British Journal of Cancer
|
October 26, 2022
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Alejo Rodriguez-Vida, Pablo Maroto, Albert Font, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2017
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations
Lisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
Nature Medicine
|
April 20, 2026
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial
Ignacio Melero, Tamara Tanos, Emiliano Calvo Aller, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
IEEE Journal of Biomedical and Health Informatics
|
May 24, 2023
Handling Ill-Conditioned Omics Data With Deep Probabilistic Models
Maria Martinez-Garcia, Pablo M Olmos
Frontiers in Oncology
|
January 3, 2025
Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports
Tamara Martos, Marta Saint-Gerons, Laura Masfarre, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|
September 10, 2019
Prognostic value of stem cell markers in glioblastoma
Francesc Alameda, José María Velarde, Cristina Carrato, et al.
Translational Oncology
|
December 18, 2020
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies
Florian Heil, Galina Babitzki, Alice Julien-Laferriere, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2012
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors
Maria Martinez-Garcia, Udai Banerji, Joan Albanell, et al.
ESMO Open
|
August 20, 2019
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer
Juan-Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas Kanonnikoff, et al.
British Journal of Cancer
|
October 26, 2022
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Alejo Rodriguez-Vida, Pablo Maroto, Albert Font, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2017
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations
Lisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
Nature Medicine
|
April 20, 2026
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial
Ignacio Melero, Tamara Tanos, Emiliano Calvo Aller, et al.
Page
of 2